Még nem toboroz
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
NCT07791732· 3. fázis· Daiichi Sankyo· Forrás
Még nem toboroz
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562· 3. fázis· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Forrás
Még nem toboroz
A study to learn how dapirolizumab pegol transfers to babies from pregnant mothers with active systemic lupus erythematosus
2025-524595-37-00· 1. fázis· UCB Biopharma· Forrás
Még nem toboroz
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408· 3. fázis· Bristol-Myers Squibb· Forrás
Még nem toboroz
Study of safety and tolerability following administration of metformin in patients with idiopathic pulmonary fibrosis (IPF)
2025-523341-10-00· 2. fázis· Philipps-Universitaet Marburg· Forrás
Még nem toboroz
An international study evaluating diagnostic and theranostic agents in patients with solid tumors and brain metastases.
2025-523824-39-01· 2. fázis· Medica Scientia Innovation Research S.L.· Forrás
Még nem toboroz
PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%
NCT07877584· 3. fázis· German Cancer Research Center· Forrás
Toboroz
Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
NCT07781644· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
SIL204-SL Treatment for Locally Advanced Pancreatic Cancer
2025-525157-39-00· 2/3. fázis· Silexion Therapeutics Ltd.· Forrás
Még nem toboroz
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
NCT07923383· 1. fázis· Sanofi· Forrás
Toboroz
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
NCT07629583· 1. fázis· Genentech, Inc.· Forrás
Még nem toboroz
A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy
NCT07623187· 2/3. fázis· Ipsen· Forrás
Még nem toboroz
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801· 3. fázis· Almirall, S.A.· Forrás
Még nem toboroz
A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)
2025-522648-42-01· 2/3. fázis· Crinetics Pharmaceuticals Inc.· Forrás
Még nem toboroz
Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden
NCT07715396· 3. fázis· AIO-Studien-gGmbH· Forrás
Toboroz
Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
2025-524928-21-00· 3. fázis· Revolution Medicines Inc.· Forrás
Toboroz
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
NCT07412704· 1/2. fázis· Bristol-Myers Squibb· Forrás
Még nem toboroz
Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
2025-524969-24-00· 3. fázis· Revolution Medicines Inc.· Forrás
Még nem toboroz
A study to investigate the immune response and safety of a vaccine against zoonotic influenza administered into the skin in adults aged 40 to 80 years
2026-525756-28-00· 1/2. fázis· University Of Antwerp· Forrás
Még nem toboroz
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
NCT07004413· 3. fázis· Charite University, Berlin, Germany· Forrás
Még nem toboroz
Clinical trial to determine the efficacy and safety of AP707 in the treatment of Borderline Personality Disorder
2024-510873-11-00· 2. fázis· Apurano Pharmaceuticals GmbH· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus
NCT07775924· 2. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07441200· 2. fázis· NS Pharma, Inc.· Forrás
Toboroz
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
2026-526654-14-01· 3. fázis· Janssen Cilag International· Forrás
Toboroz
A phase II trial of CY-101 in participants with adrenocortical cancer.
2025-522757-19-00· 2. fázis· Cancer Research UK· Forrás
Toboroz
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
NCT07711002· 3. fázis· AstraZeneca· Forrás
Toboroz
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00· 3. fázis· Incyte Corp.· Forrás
Toboroz
A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
2025-525016-41-00· 2. fázis· AstraZeneca AB· Forrás
Toboroz
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
NCT07807163· 2. fázis· Bicara Therapeutics· Forrás
Még nem toboroz
AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
2025-522190-11-01· 3. fázis· Universitaetsklinikum Schleswig-Holstein AöR· Forrás
Még nem toboroz
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
NCT07178730· 3. fázis· Women's Cancer Study Group GmbH· Forrás
Toboroz
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
2025-524335-39-00· 3. fázis· Gilead Sciences Inc.· Forrás
Toboroz
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
NCT07247162· 4. fázis· RECORDATI GROUP· Forrás
Toboroz
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· 3. fázis· AstraZeneca· Forrás
Toboroz
A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.
2025-524488-18-00· 2. fázis· Astellas Pharma Global Development Inc.· Forrás
Toboroz
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
2025-525105-20-00· 1/2. fázis· AbbVie Deutschland GmbH & Co. KG· Forrás
Még nem toboroz
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.
2026-525883-17-00· 3. fázis· Genmab A/S· Forrás
Toboroz
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
NCT07636811· 2. fázis· Alnylam Pharmaceuticals· Forrás
Még nem toboroz
A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)
NCT07760818· 2. fázis· argenx· Forrás
Még nem toboroz
An open-label study to evaluate the effect of crinecerfont on androgen reduction and related outcomes in adults with classic CAH
2025-524282-24-00· 3. fázis· Neurocrine Biosciences Inc.· Forrás
Még nem toboroz
A Study of PRO-203 in Healthy Volunteers and Participants with Systemic Sclerosis
2026-526659-70-00· 1. fázis· Prolium Bioscience Inc.· Forrás
Toboroz
BGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer
NCT07492641· 3. fázis· BeOne Medicines I GmbH· Forrás
Toboroz
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
NCT07673887· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
2025-523087-20-00· 3. fázis· Avidity Biosciences Inc.· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07481981· 3. fázis· Insmed Incorporated· Forrás
Toboroz
The RAPID-Elapse study: Can the drug bupropion improve fatigue symptoms in patients with long COVID?
2025-524443-12-00· 2. fázis· Goethe University Frankfurt· Forrás
Toboroz
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
2025-523670-17-00· 3. fázis· AstraZeneca AB· Forrás
Toboroz
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
NCT07318610· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
NCT07600476· 1. fázis· Kupando GmbH· Forrás
Showing 50 of 153.